Precision BioSciences Inc

Precision BioSciences, Inc. is a clinical-stage gene editing company that develops in vivo gene editing therapies, including gene insertion, excision, and elimination, in the United States. Its ARCUS genome editing platform is designed for DNA insertion, removal, and repair. The company's pipeline includes PBGENE-HBV for chronic hepatitis B virus, PBGENE-DMD (Excision) for Duchenne muscular dystrophy, PBGENE-3243 for m.3243-associated mitochondrial diseases, and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. for azercabtagene zapreleucel in autoimmune diseases and other indications, and with iECURE, Inc. for ARCUS-mediated targeted gene insertion. Precision BioSciences was incorporated in 2006 and is headquartered in Durham, North Carolina.